Detalhe da pesquisa
1.
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Blood
; 143(5): 404-416, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890149
2.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Blood
; 143(6): 496-506, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879047
3.
HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Blood
; 2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38683966
4.
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.
Clin Infect Dis
; 78(4): 1022-1032, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37975819
5.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Lancet
; 402(10402): 641-654, 2023 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37295445
6.
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Blood
; 139(26): 3722-3731, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35439295
7.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Lancet Oncol
; 24(7): 811-822, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414012
8.
Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy.
Am J Transplant
; 23(3): 416-422, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748802
9.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
10.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Blood
; 137(3): 323-335, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32967009
11.
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen.
Acta Haematol
; 2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708877
12.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 23(1): 91-103, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34895487
13.
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
J Cell Mol Med
; 26(24): 5976-5983, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36453136
14.
Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors.
Blood
; 136(13): 1499-1506, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32603426
15.
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.
Blood
; 135(19): 1650-1660, 2020 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32076701
16.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet
; 396(10254): 839-852, 2020 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888407
17.
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
Blood
; 134(7): 636-640, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31648294
18.
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Blood
; 133(15): 1652-1663, 2019 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30728140
19.
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Blood
; 133(17): 1876-1887, 2019 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30782611
20.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Haematologica
; 106(6): 1599-1607, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32499241